A Study Investigating the Pharmacokinetic and Pharmacodynamic Properties and Safety and Tolerability of NNC0471-0119 H When Administered as Bolus in a Continuous Subcutaneous Insulin Infusion Regimen in Participants With Type 1 Diabetes

The study is looking at the effect and safety of a new fast-acting insulin (NNC0471 0119) to people with type 1 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters your bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The participants will get each study medicine administered at separate clinic visits. The study will last for about 1-3 months.

Start Date28 Jan 2025

Sponsor / Collaborator

Novo Nordisk A/S

NCT06547619

/ RecruitingEarly Phase 1IIT

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly, within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.
The purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior.

Start Date01 Oct 2024

Sponsor / Collaborator

University of Iowa

NCT06532461

/ RecruitingNot ApplicableIIT

A Randomized Controlled Trial Testing the Influence of Three- and Seven-days Insulin Infusions and Two Types of Insulin on Hyperechogenicity in Subcutis and Glycemic Variables in Children and Adolescents With Type 1 Diabetes

More and more children and adolescents are using diabetes devices attached to the skin. The attachment of infusions sets to the skin provoke allergenic or toxic eczema, the continous infusion of insulin provoke subcutaneous changes and prolonged wear time seems to increase the risk of these complication. On the other site fewer skin stripping episodes with longer wear time and filtration of the insulin may be beneficial for the skin, therefore comparing the occurrence of subcutaneous hyper echogenicity, eczema and the skin barrier in users of 3 and 7 days infusions set is highly relevant. The primary aim of present study is to investigate if the use of three days insulin infusion set is superior to seven days in preventing the occurrence of hyperechogenicity in areas recently used for insulin infusion and if the type of insulin matter comparing insulin aspart - Novo Rapid, or insulin lispro - Humalog

Start Date20 Jul 2024

Sponsor / Collaborator

Steno Diabetes Center A/S

100 Clinical Results associated with Insulin aspart

100 Translational Medicine associated with Insulin aspart

100 Patents (Medical) associated with Insulin aspart

689

Literatures (Medical) associated with Insulin aspart

01 May 2025·DIABETES RESEARCH AND CLINICAL PRACTICE

Prescription patterns and the cost of antihyperglycemic drugs in patients with diabetes mellitus in Iran from 2014 to 2019

Article

Author: Mehrizi, Reza ; Aminzade, Zahra ; Shahali, Zahra ; Arab, Maryam ; Daroudi, Rajabali ; Effatpanah, Mohammad ; Karami, Hossein ; Heidari-Foroozan, Mahsa ; Vahdani, Amir Mohammad ; Rezaee, Mehdi ; Nasehi, Mohamad Mehdi ; Ghamkhar, Leila

INTRODUCTION:

Diabetes mellitus (DM) is characterized by high blood glucose levels and abnormalities in metabolism. In 2021, 15.14% of adult Iranians had DM. The purpose of this study is to provide policymakers with actionable insights to enhance resource allocation and improve diabetes care by evaluating the prescription patterns and costs of antidiabetic medications in Iran from 2014 to 2019 in 2.5 million patients.

METHODS:

This descriptive-analytical study used data from Iran's Health Insurance prescriptions database, analyzing approximately 2.5 million diabetic patients from 2014 to 2019. Data included drug types, frequencies, costs, and patient demographics.

RESULTS:

The analysis covered 20,233,608 prescriptions. Biguanides, sulfonylureas, and Insulin were the most commonly prescribed medications. Moreover, the 40-64 age group had the highest cost. Prescription patterns varied by age, with insulin in younger patients and Metformin in older ones. General practitioners, internal medicine specialists, and endocrinologists were the primary prescribers of anti-diabetic medications. Insulin Aspart incurred the highest costs, followed by Insulin glargine and metformin. The cost of females' antidiabetic medications was 1.66 times higher than those of males.

CONCLUSION:

Insulin was the primary cost driver for antihyperglycemic medications. These cost disparities and variations in prescription patterns underscore the need for targeted interventions to improve diabetes care and manage resources effectively.

01 Mar 2025·Endocrine Practice

Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes

Article

Author: Reddy, Niyoti ; Steenkamp, Devin W ; Alexanian, Sara M ; Cheney, Michael C ; Malik, Aamir ; Murati, Jonila ; Spartano, Nicole L ; Bello-Ramos, Jenny C ; Wolpert, Howard A

OBJECTIVE:

Hyperglycemia in hospitalized patients is associated with increased morbidity and mortality. Basal-bolus insulin therapy is the treatment of choice for most patients. The efficacy of an ultrarapid vs rapid-acting insulin in hospitalized patients with diabetes has not been evaluated. We assessed noninferiority in efficacy and safety of Fiasp vs aspart (Novolog) as part of a basal-bolus insulin regimen in noncritically ill patients with type 2 diabetes in a safety-net hospital.

METHODS:

This prospective, open-label, randomized trial included 137 patients with diabetes admitted to a non-intensive care unit setting. Subjects were treated with glargine at bedtime and either Fiasp or Novolog for prandial and correction insulin. Subjects were enrolled for a minimum of 4 or maximum of 6 meal boluses. Capillary blood glucose was used for insulin adjustment and a blinded Dexcom G6 Pro captured data for study analysis. The primary endpoint was time spent in sensor glucose range 100-180 mg/dL in the 4-hour postprandial period (assessed among 106 participants with ≥ 4 meals with a 4-hour postprandial period). Time spent in hypoglycemic ranges (<70, <54, <40 mg/dL) was assessed for safety.

RESULTS:

Four-hour postprandial time in range 100-180 mg/dL was 45% in the Fiasp group vs 36% in the Novolog group (P = .012; meeting prespecified noninferiority criteria). Other glycemic metrics were similar between groups with no difference in time spent in hypoglycemic ranges.

CONCLUSION:

Fiasp provides noninferior postprandial glucose control in hospitalized patients with type 2 diabetes when compared to Novolog with no increase in rates of hypoglycemia.

01 Mar 2025·Indian journal of pediatrics

Effect of Postmeal Fast-Acting Insulin Aspart Injection on the Frequency of Hypoglycemia among Pre-School Children with Type 1 Diabetes: An Open-Label, Cross-Over, Randomized Control Trial

Article

Author: Kumar, Rakesh ; Yadav, Jaivinder ; Pattanaik, Smita ; Dayal, Devi ; Patil, Amol ; Yadav, Arti

OBJECTIVES:

To study the effect of postmeal Fast-acting insulin Aspart (Fiasp^®) on the frequency of hypoglycemia compared to premeal injection among preschool children with type 1 diabetes.

METHODS:

A single-center trial was conducted among 65 pre-school children (6 mo to 6 y) with Type 1 diabetes for at least 6 mo, on multiple daily insulin injections. Children were randomized to receive their meal bolus postmeal or premeal for the first 3 mo, followed by cross-over at 3 mo. The two groups were compared at the end of 6 mo for the change in frequency of hypoglycemia and hyperglycemia, HbA1c, glycemic variability, and parental satisfaction. Ten children (5 in each group) underwent pharmacokinetic studies. The trial was approved by Institutional Ethics Committee and registered with the Controlled Trial Registry of India vide no CTRI/2020/10/028750.

RESULTS:

Fifty-four children completed the study, with 27 children in each group. There were no significant differences in the frequency of clinical (p = 0.921), severe (p = 0.167) or serious (p = 0.753) hypoglycemia in the two groups. There were no differences in secondary outcome parameters and pharmacokinetics.

CONCLUSIONS:

The premeal or postmeal injection of Fiasp^® does not affect the frequency of hypoglycemia or other glycemic control parameters among pre-school children with Type 1 diabetes.

TRIAL REGISTRATION:

The trial is registered with the Controlled Trial Registry of India vide no CTRI/2020/10/028750.

News (Medical) associated with Insulin aspart

08 Apr 2025

·endpts.com

Novo Nordisk, HHS clash over ‘negotiation-eligible’ drugs in IRA appeals fight

Novo Nordisk focused on a unique argument in federal appeals court on Tuesday in a case that will consider the extent to which the judiciary can review which drugs HHS says are eligible for Medicare negotiation. The drugmaker is one of several companies to sue the federal government over price negotiations under the Inflation Reduction Act. But unlike other cases, Novo is challenging CMS’ decision to group together its NovoLog and Fiasp insulin products as one drug. Novo argued before the US Court of Appeals for the Third Circuit that the agency picked more “negotiation-eligible” drugs than prescribed under the statute. “This is really the first appeal that is going to squarely get into this issue about what it means to select certain drugs for the negotiation process,” Zachary Baron, director of the Health Policy and the Law Initiative at Georgetown University’s O’Neill Institute, told Endpoints News ahead of the hearing. The second round of Medicare negotiations under the IRA kicked off in earnest last month. Novo’s lawsuit concerns the first round of negotiations which concluded last year. The IRA called for the selection of “10 negotiation-eligible drugs” for the first round, but Novo alleged that CMS actually selected “more than 15 products in total.” In doing so, Novo has argued that CMS has “unlawfully rewritten the statute’s express numerical limits.” “The agency has violated the 10-drug limit in the statute,” Ashley Parrish, counsel for Novo Nordisk and an attorney at King & Spalding, said during oral arguments on Tuesday. Meanwhile, CMS has argued that the law directs it to consider data “across dosage forms and strengths of [a] drug, including new formulations of the drug,” when determining whether it qualifies for negotiation. Attorneys for the agency also said in a December court brief that a federal district court “correctly concluded that it lacked jurisdiction to review Novo’s statutory claims.” Department of Justice attorney Lindsey Powell, who represented the government on Tuesday, said the statute “tells us that that determination made by CMS, the determination of what is a negotiation eligible drug, is not subject to judicial review. That bar is quite clear in terms of its scope.” Novo recently argued that the government has “again defied” the law’s text by grouping its popular weight loss and diabetes products Ozempic, Wegovy and Rybelsus for the next cycle. The company asked the appellate court in January for an expedited decision to “clarify Novo Nordisk’s rights and CMS’s authority under the IRA.” The US Court of Appeals for the Second Circuit heard Boehringer Ingelheim’s case against the IRA’s drug pricing provisions last week. The Third Circuit heard cases from Bristol Myers Squibb, AstraZeneca and Johnson & Johnson last fall.

06 Mar 2025

·www.prnewswire.com

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States

BRIDGEWATER, N.J. and PETERSBURG, Va. and BENGALURU, India, March 6, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, today announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Continue Reading Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials. No technology transfer is involved in the agreement. Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Post this Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: "As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders. Our collaboration with Civica reflects this commitment, enabling us to expand patient access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes. Together, we are working to ensure more patients have access to high-quality, affordable insulin." Ned McCoy, President and Chief Executive Officer, Civica, Inc., said: "Civica's mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices. This includes people living with diabetes, one in five of whom have skipped, delayed, or used less insulin than was needed to save money. Our partnership with Biocon Biologics for Aspart drug substance supply will allow us to deliver on our important mission and help people who need access to Insulin Aspart. Civica will utilize our U.S.-based manufacturing operations in Petersburg, Virginia to produce prefilled pens and vials of insulin." This collaboration is in addition to Biocon Biologics' own Insulin Aspart Drug Product for the United States which is currently under U.S. Food and Drug Administration (FDA) review. There are 38.4 million people with diabetes in the United States, approximately 11.6 percent of the total population, with nearly a quarter being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic.1 1 U.S. Department of Health & Human Services, Centers for Disease Control and Prevention. "National Diabetes Statistics Report." Accessed: January 28, 2025. Last Reviewed: May 15, 2024. About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website ; Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates. Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: ; Follow-us on X (formerly Twitter) @bioconlimited and LinkedIn: Biocon for company updates. About Civica, Inc.: Civica is a non-profit generic pharmaceutical company established in 2018 to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients. Civica has built a sterile injectable manufacturing plant in Petersburg, Virginia capable of producing prefilled pens and vials of insulin. Website: Follow us on X (formerly Twitter) @civicarx and LinkedIn: CivicaRx for company updates Forward-Looking Statements: Biocon This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. SOURCE Biocon Biologics Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/in

19 Feb 2025

·www.drugs.com

FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Patients With Diabetes

WEDNESDAY, Feb. 19, 2025 -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus . Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the FDA. Administering Merilog subcutaneously five to 10 minutes before mealtime helps improve glycemic control in patients with diabetes . Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval. Serious side effects reported with Merilog include hypoglycemia, severe allergic reactions, and low potassium levels in the blood. Common side effects include injection site reactions, itching, rash, skin thickening or pitting at the injection site, weight gain, and swelling of hands and feet. "The FDA has now approved three biosimilar insulin products to treat diabetes," Peter Stein, M.D., director of the Office of New Drugs in the FDA Center for Drug Evaluation and Research, said in an agency press release. "Today’s approval highlights our continued efforts to improve the efficiency of the biosimilar approval process to help support a competitive marketplace and increase options for costly treatments, like insulin. Increasing access to safe, effective and high-quality medications at potentially lower cost remains a continued priority for the FDA." Approval of Merilog was granted to Sanofi-Aventis. More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

100 Deals associated with Insulin aspart

External Link

KEGG	Wiki	ATC	Drug Bank
D04475	Insulin aspart	A10AD05 A10AB05	DB01306

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Japan	Novo Nordisk A/S	20 Sep 2019
Diabetes Mellitus	European Union	Novo Nordisk A/S	07 Sep 1999
Diabetes Mellitus	Iceland	Novo Nordisk A/S	07 Sep 1999
Diabetes Mellitus	Liechtenstein	Novo Nordisk A/S	07 Sep 1999
Diabetes Mellitus	Norway	Novo Nordisk A/S	07 Sep 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 3	Spain	Novo Nordisk A/S	01 Apr 2005
Acute Lymphoblastic Leukemia	Phase 3	United States	Novo Nordisk A/S	01 Apr 2004
Adult Lymphoblastic Lymphoma	Phase 3	United States	Novo Nordisk A/S	01 Apr 2004
Burkitt Lymphoma	Phase 3	United States	Novo Nordisk A/S	01 Apr 2004
Lymphoma	Phase 3	United States	Novo Nordisk A/S	01 Apr 2004
Hypoglycemia	Phase 3	Australia	Novo Nordisk A/S	01 Sep 2001
Hypoglycemia	Phase 3	Croatia	Novo Nordisk A/S	01 Sep 2001
Hypoglycemia	Phase 3	Denmark	Novo Nordisk A/S	01 Sep 2001
Hypoglycemia	Phase 3	Italy	Novo Nordisk A/S	01 Sep 2001
Hypoglycemia	Phase 3	South Africa	Novo Nordisk A/S	01 Sep 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03659799 (Pubmed)	Phase 4	Diabetes Mellitus, Type 1	40	insulin type (ultra-rapid vs rapid insulin) (Rapid aspart)	nkbrrseisp(spbfspjwhk) = ljlpxmeqtx bngjpmshef (onahdiecoh )	Positive	29 Jul 2024
				insulin type (ultra-rapid vs rapid insulin) (Exercise at 60 min post meal)	yxowtqjvya(azakecifmo) = uolkmhqsua bbdcwzgyml (qefovfozin, 1.2 - 100%)
NCT04538352 (TRANSITION-T2D, CTgov)	Phase 4	Diabetes Mellitus, Type 2	60	Insulin Degludec+semaglutide+Insulin aspart (Once-weekly sc Semaglutide Combined With Once-daily Insulin)	maawbhnvqs(rbpathyuzf) = zenyhtwolp jbvnwoifse (yexcxbcspp, kqdcdoycix - ppccmpvykg) View more	-	29 Jul 2024
				Insulin Degludec+Insulin aspart (MDI Requiring Multiple Daily Injections of Insulin)	maawbhnvqs(rbpathyuzf) = uujmwqzrmo jbvnwoifse (yexcxbcspp, zxfhswigkv - tjzramnvth) View more
820-P (ADA2024)	Not Applicable	Diabetes Mellitus, Type 1	-	Faster-Acting Insulin Aspart (Fiasp)	bxvsrytzyo(ewgvvldztg) = nvmwksnefa qvwvvzfpyn (miqvorczts, 12.3) View more	Positive	14 Jun 2024
				Insulin Aspart (Iasp)	bxvsrytzyo(ewgvvldztg) = hpacijmffi qvwvvzfpyn (miqvorczts, 12.1) View more
NCT04588259 (CTgov)	Phase 3	Diabetes Mellitus, Type 1 \| Diabetes Mellitus, Type 2	331	Insulin degludec+Faster aspart	tfnuknzyyc(yjuedxdxdk) = fjrgvjszpx wfskuvmagm (chpxhqlbha, 0.63) View more	-	20 Mar 2024
NCT04460326 (In-FI, CTgov)	Phase 3	Diabetes Mellitus, Type 2	137	Insulin Glargine+NovoLog (Group 1 Insulin Glargine and Novolog)	tfeaqvsxdp(rjdufjyrot) = zpokfqaqky txkewkuxkm (eeenzirydl, 29.78) View more	-	19 Mar 2024
				Insulin Glargine+Insulin Fiasp (Group 2 Insulin Glargine and Fiasp)	tfeaqvsxdp(rjdufjyrot) = wawgpxgrkv txkewkuxkm (eeenzirydl, 32.63) View more
NCT00913497 (CTgov)	Phase 4	Diabetes Mellitus, Type 1	16	insulin glulisine (Insulin Glulisine)	xezxsuvpwg(vansirtqvb) = ppvmichcsq fghbydrpaz (qaayewemyk, 15.7) View more	-	18 Sep 2023
				Insulin Aspart (Insulin Aspart)	xezxsuvpwg(vansirtqvb) = pokiwnmraq fghbydrpaz (qaayewemyk, 14.7) View more
NCT04853030 (Pubmed \| Diabetes Technol Ther)	Not Applicable	Diabetes Mellitus, Type 1	30	Faster Insulin Aspart	rnfpxdzsvy(lnqpybkkfi) = igcshalkct bzxhzsnbag (kvpsiafnno ) View more	Negative	01 Sep 2023
				Standard Insulin Aspart	rnfpxdzsvy(lnqpybkkfi) = rdpeozxrax bzxhzsnbag (kvpsiafnno ) View more
NCT03895515 (Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 1	178	Fast-Acting Insulin Aspart	kwconbjcwj(fejvcyyryj) = hrrnsznkul tlgrvuwzhs (yghvqhgpxs )	Positive	14 Jul 2023
CopenFast Trial (ADA2023)	Not Applicable	Diabetes Mellitus, Type 1	216	Faster-acting insulin aspart	reupbxyxai(zmsdouidou) = vlebegdoye yggjqlpzkn (ehqihnkixs, 38 - 46) View more	-	20 Jun 2023
				Insulin aspart	reupbxyxai(zmsdouidou) = avakjbdobo yggjqlpzkn (ehqihnkixs, 39 - 46) View more
ADA2023	Not Applicable	-	29	AT247	ovjlwggpiz(zxzmaaisvq) = sgsgttyszw rzlnimqfrl (dephwwycyg )	-	20 Jun 2023
				NovoLog	ovjlwggpiz(zxzmaaisvq) = wgvkbkrozt rzlnimqfrl (dephwwycyg, *)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis